Absci Corporation (NASDAQ:ABSI) is one of the 8 Best Genomics Stocks to Buy According to Analysts.
On June 4, Leerink initiated coverage on Absci Corporation (NASDAQ:ABSI) with an Outperform rating and a $12 price target
The analyst stated that its “AI-native, clinical-stage story” is anchored by lead asset ABS-20 in Phase 1/2 for androgenetic alopecia, with Phase 2 in endometriosis expected to begin in Q4 2026. The firm flagged an “18-month catalyst path” with multiple readouts, calling it highly binary but among the most attractive in its coverage. Separately, looking forward, Absci Corporation (NASDAQ:ABSI)’s CEO Sean McClain said that 2026 will be a “data-rich year.” He also stated that ABS-201, a long-acting anti-PRLR antibody, could introduce a new mechanism in alopecia with infrequent dosing.
The corporation said it completed dosing across four single ascending dose cohorts. It reported favorable safety and PK trends while starting multiple ascending dose cohorts. The company announced ABS-202, a preclinical anti-PRLR program.